Core Viewpoint - The company will hold an investor briefing on October 22, 2025, to discuss its Q3 2025 financial results and address common investor concerns [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for October 22, 2025, from 16:00 to 17:00 [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [4][5]. - Participants will include the company's chairman, independent directors, president, CFO, and board secretary [4]. Group 2: Participation Information - Investors can join the briefing online via the Shanghai Stock Exchange Roadshow Center [5]. - Questions can be submitted from October 15 to October 21, 2025, through the Roadshow Center's website or via the company's email [5]. - The company will respond to commonly asked questions during the briefing [3][5]. Group 3: Contact Information - Contact persons for inquiries are Cao Hong and Wang Miao, with a provided phone number [6]. - The company's email for investor questions is ir.jmjt@whjm.com [6]. Group 4: Additional Information - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [7]. - The company expresses gratitude for investor support and encourages participation in the online briefing [7].

证券代码：600976 证券简称：健民集团 公告编号：2025-035 健民药业集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 10 月 22 日(星期三)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允 许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 (一) 会议召开时间：2025 年 10 月 22 日(星期三)下午 16:00-17:00 (二) 会议召开地点：上海证券交易所上证路演中心 (三) 会议召开方式：上证路演中心网络文字互动 三、参加人员 公司董事长袁平东先生、独立董事郭云沛先生、 ...

截至发稿，健民集团市值为62亿元。 每经头条（nbdtoutiao）——天水麻辣烫、淄博烧烤、荣昌卤鹅⋯⋯"泼天流量"退去后，这些城市怎么 样了？ 每经AI快讯，健民集团（SH 600976，收盘价：40.29元）10月10日晚间发布关于对子公司银行授信额度 提供担保的实施公告。公告称，截至本公告披露日，公司对控股子公司提供的担保总额度为3.56亿元 （含本次），占公司2024年经审计净资产约24.35亿元的14.62%，截至2025年9月30日，公司对控股子公 司提供的担保余额为1.27亿元。 2024年1至12月份，健民集团的营业收入构成为：医药工业占比49.83%，医药商业占比49.56%，其他业 务占比0.6%。 （记者 王可然） ...

证券代码：600976 证券简称：健民集团 公告编号：2025-034 健民药业集团股份有限公司 关于对子公司银行授信额度提供担保的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特别风险提示：公司本次担保的担保对象维生公司的资产负债率超过 70%， 敬请广大投资者注意担保风险。 为支持子公司业务发展，公司将为全资子公司武汉健民药业集团维生药品有 限责任公司（以下简称：维生公司）向中信银行股份有限公司武汉分行申请的综 合授信敞口额度提供连带责任保证。现将有关情况公告如下： 重要内容提示： 被担保人为全资子公司武汉健民药业集团维生药品有限责任公司（以下简 称：维生公司）； 公司本次为维生公司提供的担保金额为 5,000 万元，截至本公告披露日公 司已实际为维生公司提供的担保余额为 0 元； 一、担保情况概述 （一）担保情况简介 被担保人：武汉健民药业集团维生药品有限责任公司 债权人：中信银行股份有限公司武汉分行 担保金额：5,000 万元 担保方式：连带责任保证 担保期限：一年 担保情况：公司为维生公司向中信银行 ...

Group 1 - The core viewpoint of the article highlights the strategic partnerships formed by KJ Supply Chain Co., Ltd. with four major brands across different industries to enhance digital transformation and intelligent upgrades in supply chain management [2][3]. - KJ Supply Chain will provide customized smart supply chain solutions based on the specific characteristics and needs of each industry partner [2][3]. - The collaboration with Lenovo focuses on local storage and rapid allocation of goods, leveraging KJ's extensive warehousing network of over 160 locations [2][4]. Group 2 - The partnership with Jianmin Pharmaceutical aims to optimize supply chain management, enhance operational efficiency, and reduce delivery times and damage rates [3][4]. - KJ Supply Chain will offer one-stop operational services for e-commerce channels in collaboration with Zhenyan Biotechnology, utilizing major platforms like Tmall, JD, and Amazon [3][4]. - The cooperation with Heidi Garden will explore innovative paths in smart agriculture, establishing a standardized operational system across the entire supply chain from procurement to delivery [3][4]. Group 3 - KJ Supply Chain has a strong foundation in the smart supply chain sector, with a peak order processing capacity of 5 million orders per day and coverage in approximately 300 cities nationwide [4]. - The company has also established overseas warehouse networks in several Southeast Asian countries, indicating its capability in both domestic and cross-border logistics [4]. - Future plans include continuing to focus on customer needs and leveraging industry experience and technological innovation to deepen the application of smart supply chains across various sectors [4].

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

Financing Activities - On September 12, Jianmin Group (600976) had a financing buy-in of 17.1361 million yuan and a financing repayment of 16.3358 million yuan, resulting in a net financing buy of 800,300 yuan, with a financing balance of 210 million yuan [1] - Over the past three trading days, the cumulative net buy has reached 3.2865 million yuan, and in the last 20 trading days, there have been 12 days with net financing buy [1] Financing and Margin Data - The financing balance on September 12 was 210 million yuan, which represents an increase of 0.37% compared to the previous day [4] - The financing balance has shown a consistent upward trend, with notable increases of 6.60% and 6.13% on September 9 and September 8, respectively [4] Margin Trading - On September 12, there were no shares sold short, but 400 shares were repaid, resulting in a net short buy of 400 shares, with a remaining short balance of 17,400 shares [3] - The short balance on September 12 was valued at 736,500 yuan [3]

Market Overview - The Chinese traditional medicine sector rose by 1.24% on September 8, with Jianmin Group leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Top Performers - Jianmin Group (600976) closed at 43.36, up 4.23% with a trading volume of 66,000 shares and a turnover of 280 million yuan [1] - Qizheng Pharmaceutical (002287) closed at 28.64, up 4.15% with a trading volume of 173,000 shares [1] - Zhaoli Pharmaceutical (300181) closed at 18.86, up 3.97% with a trading volume of 222,100 shares [1] - Yiling Pharmaceutical (002603) closed at 17.03, up 3.90% with a trading volume of 447,300 shares [1] Underperformers - ST Xiangxue (300147) closed at 11.05, down 1.69% with a trading volume of 211,600 shares [2] - Zhendong Pharmaceutical (300158) closed at 7.96, down 0.50% with a trading volume of 384,600 shares [2] - Taiji Group (600129) closed at 22.29, down 0.45% with a trading volume of 180,300 shares [2] Capital Flow - The traditional medicine sector experienced a net outflow of 40.80 million yuan from institutional investors and 45.85 million yuan from speculative funds, while retail investors saw a net inflow of 86.65 million yuan [2] - Zhaoli Pharmaceutical (300181) had a net inflow of 62.71 million yuan from institutional investors, while retail investors had a net outflow of 54.18 million yuan [3] - Jianmin Group (600329) saw a net inflow of 28.68 million yuan from institutional investors, with retail investors experiencing a net outflow of 22.12 million yuan [3]

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Group 1 - The core point of the announcement is that Jianmin Pharmaceutical Group has received approval for the oral solution of Furosemide, which is a diuretic used for treating edema and hypertension [1][2]. - The drug is classified as a prescription medication and is registered as a Class 3 chemical drug in China, with a shelf life until August 25, 2030 [1][2]. - The oral solution form of Furosemide is particularly suitable for children, enhancing medication safety and compliance compared to traditional tablet and injection forms [2]. Group 2 - The total research and development investment for the Furosemide oral solution reached approximately RMB 8.0523 million as of July 31, 2025 [2]. - In the Chinese market, Furosemide has various formulations, including tablets and injections, with sales figures for Furosemide reaching RMB 690 million in 2022, RMB 735 million in 2023, and RMB 603 million in 2024 [3]. - The approval of the Furosemide oral solution is expected to enrich the company's product line and enhance its core competitiveness, although short-term impacts on financial performance are anticipated to be limited [3].